← Leaderboards
Sunil J Advani
University Of California, San Diego
$4,585,067
Attributed
$4,585,067
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $887.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,585,067 · 4
By mechanism
R37$2,486,645 · 1
R01$1,572,584 · 1
R21$370,838 · 1
R03$155,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Diego
Same institution · by research overlap
- Shaochen Chen$8,013,482
- Dyann F Wirth$23,065,036
- Elizabeth A Winzeler$16,284,816
- Jason Keith Sicklick$6,608,057
- Juliana Idoyaga$10,094,679
Others in their field
Top investigators on “Link”
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- David R. Weir · University Of Michigan At Ann Arbor$206,261,870
- Clare E Reimers · Gordon Research Conferences$205,233,456
- Demian A Bailey · Oregon State University$205,233,456
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Greg Ulses · Consortium For Ocean Leadership, Inc$140,113,248
Research focus
LinkImproved OutcomeToxic EffectRadiosensitizationTumorInnovationResponseRadiation-Sensitizing AgentsIonizing RadiationRadiation TherapyMorbidity - Disease RateDna RepairCancer PatientChemotherapyNeoplastic CellCellsPharmaceutical PreparationsNormal Tissue MorphologyDna DamageCurative TreatmentsOrganCytotoxicAntibody-Drug ConjugatesTumor Xenograft
Grant awards (14)
Spatially precise radio-chemo-immunotherapy using antibody conjugates$533,079
R01 · FY2025 · CA · contact PI
Spatially precise radio-chemo-immunotherapy using antibody conjugates$506,426
R01 · FY2024 · CA · contact PI
Elucidation and therapeutic exploitation of PAK mediated radioresistance$343,355
R37 · FY2024 · CA · contact PI
Spatially precise radio-chemo-immunotherapy using antibody conjugates$533,079
R01 · FY2023 · CA · contact PI
Elucidation and therapeutic exploitation of PAK mediated radioresistance$354,197
R37 · FY2023 · CA · contact PI
Elucidation and therapeutic exploitation of PAK mediated radioresistance$361,425
R37 · FY2022 · CA · contact PI
Elucidation and therapeutic exploitation of PAK mediated radioresistance$360,759
R37 · FY2021 · CA · contact PI
Elucidation and therapeutic exploitation of PAK mediated radioresistance$360,281
R37 · FY2020 · CA · contact PI
Elucidation and therapeutic exploitation of PAK mediated radioresistance$348,825
R37 · FY2019 · CA · contact PI
Elucidation and therapeutic exploitation of PAK mediated radioresistance$357,803
R37 · FY2018 · CA · contact PI
Developing targeted activatable peptides to amplify radiosensitizer delivery$77,500
R03 · FY2018 · CA · contact PI
Restricting radiosensitization through ErbB targeted antibody drug conjugates$202,275
R21 · FY2017 · CA · contact PI
Developing targeted activatable peptides to amplify radiosensitizer delivery$77,500
R03 · FY2017 · CA · contact PI
Restricting radiosensitization through ErbB targeted antibody drug conjugates$168,563
R21 · FY2016 · CA · contact PI